
OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Structure-based design of prefusion-stabilized SARS-CoV-2 spikes
Ching‐Lin Hsieh, Jory A. Goldsmith, Jeffrey M. Schaub, et al.
Science (2020) Vol. 369, Iss. 6510, pp. 1501-1505
Open Access | Times Cited: 1242
Ching‐Lin Hsieh, Jory A. Goldsmith, Jeffrey M. Schaub, et al.
Science (2020) Vol. 369, Iss. 6510, pp. 1501-1505
Open Access | Times Cited: 1242
Showing 1-25 of 1242 citing articles:
SARS-CoV-2 vaccines in development
Florian Krammer
Nature (2020) Vol. 586, Iss. 7830, pp. 516-527
Open Access | Times Cited: 2077
Florian Krammer
Nature (2020) Vol. 586, Iss. 7830, pp. 516-527
Open Access | Times Cited: 2077
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
Christopher O. Barnes, Claudia A. Jette, Morgan E. Abernathy, et al.
Nature (2020) Vol. 588, Iss. 7839, pp. 682-687
Open Access | Times Cited: 1677
Christopher O. Barnes, Claudia A. Jette, Morgan E. Abernathy, et al.
Nature (2020) Vol. 588, Iss. 7839, pp. 682-687
Open Access | Times Cited: 1677
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
Zijun Wang, Fabian Schmidt, Yiska Weisblum, et al.
Nature (2021) Vol. 592, Iss. 7855, pp. 616-622
Open Access | Times Cited: 1442
Zijun Wang, Fabian Schmidt, Yiska Weisblum, et al.
Nature (2021) Vol. 592, Iss. 7855, pp. 616-622
Open Access | Times Cited: 1442
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants
Yiska Weisblum, Fabian Schmidt, Fengwen Zhang, et al.
eLife (2020) Vol. 9
Open Access | Times Cited: 1418
Yiska Weisblum, Fabian Schmidt, Fengwen Zhang, et al.
eLife (2020) Vol. 9
Open Access | Times Cited: 1418
BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection
Yunlong Cao, Ayijiang Yisimayi, Fanchong Jian, et al.
Nature (2022) Vol. 608, Iss. 7923, pp. 593-602
Open Access | Times Cited: 1218
Yunlong Cao, Ayijiang Yisimayi, Fanchong Jian, et al.
Nature (2022) Vol. 608, Iss. 7923, pp. 593-602
Open Access | Times Cited: 1218
Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition
Allison J. Greaney, Tyler N. Starr, Pavlo Gilchuk, et al.
Cell Host & Microbe (2020) Vol. 29, Iss. 1, pp. 44-57.e9
Open Access | Times Cited: 1075
Allison J. Greaney, Tyler N. Starr, Pavlo Gilchuk, et al.
Cell Host & Microbe (2020) Vol. 29, Iss. 1, pp. 44-57.e9
Open Access | Times Cited: 1075
Viral targets for vaccines against COVID-19
Lianpan Dai, George F. Gao
Nature reviews. Immunology (2020) Vol. 21, Iss. 2, pp. 73-82
Open Access | Times Cited: 1063
Lianpan Dai, George F. Gao
Nature reviews. Immunology (2020) Vol. 21, Iss. 2, pp. 73-82
Open Access | Times Cited: 1063
SARS-CoV-2 variant biology: immune escape, transmission and fitness
Alessandro M. Carabelli, Thomas P. Peacock, Lucy Thorne, et al.
Nature Reviews Microbiology (2023)
Open Access | Times Cited: 989
Alessandro M. Carabelli, Thomas P. Peacock, Lucy Thorne, et al.
Nature Reviews Microbiology (2023)
Open Access | Times Cited: 989
Beyond Shielding: The Roles of Glycans in the SARS-CoV-2 Spike Protein
Lorenzo Casalino, Zied Gaieb, Jory A. Goldsmith, et al.
ACS Central Science (2020) Vol. 6, Iss. 10, pp. 1722-1734
Open Access | Times Cited: 950
Lorenzo Casalino, Zied Gaieb, Jory A. Goldsmith, et al.
ACS Central Science (2020) Vol. 6, Iss. 10, pp. 1722-1734
Open Access | Times Cited: 950
N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2
Matthew McCallum, Anna De Marco, Florian A. Lempp, et al.
Cell (2021) Vol. 184, Iss. 9, pp. 2332-2347.e16
Open Access | Times Cited: 947
Matthew McCallum, Anna De Marco, Florian A. Lempp, et al.
Cell (2021) Vol. 184, Iss. 9, pp. 2332-2347.e16
Open Access | Times Cited: 947
SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates
Nikolaos C. Kyriakidis, Andrés López‐Cortés, Eduardo Vásconez, et al.
npj Vaccines (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 691
Nikolaos C. Kyriakidis, Andrés López‐Cortés, Eduardo Vásconez, et al.
npj Vaccines (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 691
De novo design of picomolar SARS-CoV-2 miniprotein inhibitors
Longxing Cao, Inna Goreshnik, Brian Coventry, et al.
Science (2020) Vol. 370, Iss. 6515, pp. 426-431
Open Access | Times Cited: 603
Longxing Cao, Inna Goreshnik, Brian Coventry, et al.
Science (2020) Vol. 370, Iss. 6515, pp. 426-431
Open Access | Times Cited: 603
Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms
M. Alejandra Tortorici, Martina Beltramello, Florian A. Lempp, et al.
Science (2020) Vol. 370, Iss. 6519, pp. 950-957
Open Access | Times Cited: 587
M. Alejandra Tortorici, Martina Beltramello, Florian A. Lempp, et al.
Science (2020) Vol. 370, Iss. 6519, pp. 950-957
Open Access | Times Cited: 587
mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection
Leonidas Stamatatos, Julie Czartoski, Yu-Hsin Wan, et al.
Science (2021) Vol. 372, Iss. 6549, pp. 1413-1418
Open Access | Times Cited: 580
Leonidas Stamatatos, Julie Czartoski, Yu-Hsin Wan, et al.
Science (2021) Vol. 372, Iss. 6549, pp. 1413-1418
Open Access | Times Cited: 580
Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite
Gabriele Cerutti, Yicheng Guo, Tongqing Zhou, et al.
Cell Host & Microbe (2021) Vol. 29, Iss. 5, pp. 819-833.e7
Open Access | Times Cited: 540
Gabriele Cerutti, Yicheng Guo, Tongqing Zhou, et al.
Cell Host & Microbe (2021) Vol. 29, Iss. 5, pp. 819-833.e7
Open Access | Times Cited: 540
A systematic review of SARS-CoV-2 vaccine candidates
Yetian Dong, Tong Dai, Yujun Wei, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 539
Yetian Dong, Tong Dai, Yujun Wei, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 539
Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement
Matthew McCallum, Nadine Czudnochowski, Laura E. Rosen, et al.
Science (2022) Vol. 375, Iss. 6583, pp. 864-868
Open Access | Times Cited: 509
Matthew McCallum, Nadine Czudnochowski, Laura E. Rosen, et al.
Science (2022) Vol. 375, Iss. 6583, pp. 864-868
Open Access | Times Cited: 509
Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2
Alexandra C. Walls, Brooke Fiala, Alexandra Schäfer, et al.
Cell (2020) Vol. 183, Iss. 5, pp. 1367-1382.e17
Open Access | Times Cited: 503
Alexandra C. Walls, Brooke Fiala, Alexandra Schäfer, et al.
Cell (2020) Vol. 183, Iss. 5, pp. 1367-1382.e17
Open Access | Times Cited: 503
SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape
Tyler N. Starr, Nadine Czudnochowski, Zhuoming Liu, et al.
Nature (2021) Vol. 597, Iss. 7874, pp. 97-102
Open Access | Times Cited: 502
Tyler N. Starr, Nadine Czudnochowski, Zhuoming Liu, et al.
Nature (2021) Vol. 597, Iss. 7874, pp. 97-102
Open Access | Times Cited: 502
Controlling the SARS-CoV-2 spike glycoprotein conformation
Rory Henderson, Robert J. Edwards, Katayoun Mansouri, et al.
Nature Structural & Molecular Biology (2020) Vol. 27, Iss. 10, pp. 925-933
Open Access | Times Cited: 448
Rory Henderson, Robert J. Edwards, Katayoun Mansouri, et al.
Nature Structural & Molecular Biology (2020) Vol. 27, Iss. 10, pp. 925-933
Open Access | Times Cited: 448
SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern
Matthew McCallum, Jessica Bassi, Anna De Marco, et al.
Science (2021) Vol. 373, Iss. 6555, pp. 648-654
Open Access | Times Cited: 441
Matthew McCallum, Jessica Bassi, Anna De Marco, et al.
Science (2021) Vol. 373, Iss. 6555, pp. 648-654
Open Access | Times Cited: 441
The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates
Bryan E. Jones, Patricia Brown‐Augsburger, Kizzmekia S. Corbett, et al.
Science Translational Medicine (2021) Vol. 13, Iss. 593
Open Access | Times Cited: 427
Bryan E. Jones, Patricia Brown‐Augsburger, Kizzmekia S. Corbett, et al.
Science Translational Medicine (2021) Vol. 13, Iss. 593
Open Access | Times Cited: 427
Advances in COVID-19 mRNA vaccine development
Enyue Fang, Xiaohui Liu, Miao Li, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 409
Enyue Fang, Xiaohui Liu, Miao Li, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 409
The SARS-CoV-2 Spike Glycoprotein Biosynthesis, Structure, Function, and Antigenicity: Implications for the Design of Spike-Based Vaccine Immunogens
Liangwei Duan, Qianqian Zheng, Hongxia Zhang, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 407
Liangwei Duan, Qianqian Zheng, Hongxia Zhang, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 407
Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells
Kristen W. Cohen, Susanne L. Linderman, Zoe Moodie, et al.
Cell Reports Medicine (2021) Vol. 2, Iss. 7, pp. 100354-100354
Open Access | Times Cited: 405
Kristen W. Cohen, Susanne L. Linderman, Zoe Moodie, et al.
Cell Reports Medicine (2021) Vol. 2, Iss. 7, pp. 100354-100354
Open Access | Times Cited: 405